The next big shake-up in the GLP-1 market? (Part 1 of 3)
Beyond BiotechAI Summary
→ WHAT IT COVERS Valeriia Simanovskaia, founder and CEO of Bio Brokers, analyzes the GLP-1 market's shifting dynamics in 2025–2026, covering patent expiries in India, China, and Canada, the rise of oral formulations, monthly-dosing candidates like Amgen's maritide, and where capital is concentrating across obesity biotech. → KEY INSIGHTS - **Persistence gap:** Only 8% of patients initiating GLP-1 therapy for obesity without diabetes remain persistent at three years, rising to 14% for newer high-potency products. Withdrawal data shows patients regain roughly two-thirds of semaglutide-induced weight loss within one year of stopping, making maintenance the market's most underserved clinical problem. - **Oral GLP-1 segmentation:** FDA approved oral Wegovy (25mg daily, strict fasting requirements) in December 2025 and Lilly's Orforglipron in April 2026 (taken with or without food, room-temperature storage). These two oral products differ significantly in administration burden and manufacturing architecture, meaning they will likely compete as distinct segments rather than direct substitutes. - **Generic semaglutide is already real:** Health Canada approved the first generic semaglutide referencing Wegovy in June 2026, and India saw multiple generic launches after its March 2026 patent expiry, with pricing discounts of at least 50–60%. Biotech investors and founders should treat these markets as live experiments in what US pricing and access will look like post-2032. - **Differentiation requires a future-proof niche:** Founders entering obesity drug development should identify one specific limitation of the future standard of care — tolerability, lean mass preservation, less frequent dosing, oral delivery, or a complementary mechanism — and design clinical trials against the competitive landscape at projected launch, not today's market, which will include oral GLP-1s, triple agonists, and cheaper generics. - **Indication stacking carries double-counting risk:** Cardiovascular, MASH, CKD, sleep apnea, and obesity populations overlap heavily — the same patient can carry all five diagnoses. Each indication also requires a separate evidentiary package; Wegovy's cardiovascular label required a 17,600-patient outcomes trial, while its MASH approval remains accelerated and contingent on confirmatory data. → NOTABLE MOMENT Simanovskaia highlights that adding a myostatin inhibitor to tirzepatide preserved 1.9 kilograms of additional lean mass — roughly 55% more — versus tirzepatide alone in a 2026 Nature Medicine phase two trial, suggesting the next competitive frontier is combination architecture, not simply higher peak weight-loss percentages. 💼 SPONSORS None detected 🏷️ GLP-1 Market, Obesity Pharmacotherapy, Biotech M&A, Oral Weight-Loss Drugs, Patent Expiry